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HIV DRUG RESISTANCE: PROBLEMS AND PERSPECTIVES
Abstract
Access to combination antiretroviral treatment (ART) has improved greatly over recent years. At the  
end of 2011, more than eight million HIV infected people were receiving antiretroviral therapy in 
low-income  and  middle-income  countries.  ART  generally  works  well  in  keeping  the  virus 
suppressed and the  patient  healthy.  However,  treatment  only works as  long as  the virus  is  not 
resistant against the drugs used. In the last decades, HIV treatments have become better and better 
at slowing down the evolution of drug resistance, so that some patients are treated for many years 
without  having any resistance  problems.  However,  for  some patients,  especially  in  low-income 
countries, drug resistance is still  a serious threat to their  health. This essay will  review what is  
known about transmitted and acquired drug resistance, multi-class drug resistance,  resistance to 
newer drugs, resistance due to treatment for the prevention of mother-to-child transmission, the role 
of minority variants (low-frequency drug-resistance mutations), and resistance due to pre-exposure 
prophylaxis.  
Introduction
More and more  HIV patients  have  access  to  combination  antiretroviral  treatment  (ART).  ART 
generally works well in keeping the virus suppressed and the patient healthy. However, treatment 
only works as long as the virus is not resistant against the drugs used. When the first antiretrovirals 
came on the market in the 1980s, drug resistance was a certain outcome for all patients, and the 
duration of successful treatment was limited. Nowadays, some patients are treated for many years 
without having any resistance problems, while for others, drug resistance is a serious threat to their 
health. 
Throughout this essay I will  contrast the situation in high-income countries, where combination 
therapy has been common since the late 1990s (North America, Europe, Japan, Australia), with the 
situation in low- and middle-income countries, where, in some areas, treatment has only recently 
become available. At the end of 2011, more than eight million people were receiving antiretroviral 
therapy in low- and middle-income countries. The number of people on treatment increased most 
rapidly in sub-saharan Africa, from just 100,000 patients on treatment in 2003 to 6.2 million in 2011 
(UNAIDS, 2012). These numbers are impressive and have changed the lives of HIV patients in 
those regions. However, the situation of patients in low-income countries is still different in several 
ways from the situation of patients in high-income countries. For example, viral load monitoring 
and viral genotyping, which are standard practice in high-income countries, are almost completely 
unavailable in low-income countries. 
In order to cover different aspects of drug resistance, this essay is split in seven parts. (1) I will start 
by describing the problem of transmitted drug resistance. Next (2), I will elaborate on acquired 
drug resistance during ART, which is more common than transmitted drug resistance. I will then 
(3)  describe  which  patients  are  at  risk  of  developing  multi-class  drug resistance (MDR) and 
discuss briefly the treatment options that are available to them. (4) In the last decade, several new 
drugs, in existing as well as new drug classes, have become available. I will describe what is known 
about  resistance to some of these new drugs.  (5) In low- and middle-income countries, many 
patients  are  exposed  to  antiretroviral  drugs  in  the  context  of  prevention  of  mother-to-child-
transmission (PMTCT). I will explain how PMTCT can lead to a high risk of drug resistance. (6) 
Next,  I  will  look  at  what  is  known about drug-resistance  mutations  which  are  present  at  low 
frequency in the patient, which are known as minority variants. (7) Finally, I will touch upon the 
issue  of  drug resistance  due  to  the  use  of  antiretroviral  drugs  to  prevent  HIV infections  (pre-
exposure prophylaxis or PrEP).   
1. Transmitted Drug Resistance
Drug-resistant HIV strains can be transmitted from one patient to another. Due to such transmitted 
drug resistance, a newly infected patient may carry a drug-resistant virus even though he or she has 
not yet used antiretroviral drugs. From the early days of HIV treatment, researchers have feared that 
drug-resistant  strains  would  reach  high  frequencies  among  newly  infected  patients,  rendering 
certain drugs entirely useless. Fortunately, this has never happened with HIV drugs. In comparison, 
many malaria drugs have been withdrawn from use by national authorities because of widespread 
transmission  of  drug  resistant  malaria  parasites  (Read  and  Huijben,  2009).  Transmitted  drug 
resistance  does  occur  in  HIV,  but  the  numbers  have  remained  relatively  low.  In  high-income 
countries, between 7 and 17% of newly infected patients carry at least one major drug-resistance 
mutation, usually a mutation that confers resistance to one of two drug classes: nucleoside reverse 
transcriptase inhibitors (NRTI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) (WHO, 
2012,  Frentz  et  al.,  2012).  The  transmission  of  drug  resistance  to  the  third  major  drug-class 
(protease inhibitors, PIs) is less common.  
In middle and low-income countries, the levels of transmitted drug resistance are lower than in 
high-income countries, but this will  likely change with time. In 2006, the member states of the 
United Nations agreed to aim for universal access to treatment in 2010 (UNAIDS, 2007). The rapid 
increase of  availability  of  ART in middle-  and low-income countries following this decision is 
referred to  as the “rollout  of ART”. There is  evidence for a rapid increase in  transmitted drug 
resistance in the years after rollout of ART in east and southern Africa (Gupta et al., 2012). This is  
not surprising, because ART went from being virtually non-existent to being quite common in these 
regions.  The  prevalence  of  transmitted drug resistance  in  middle-  and low-income countries  is 
estimated to be around 7% (WHO, 2012). 
Even though transmitted drug resistance is somewhat less common in low-income countries than in 
high-income countries, the impact may be higher for patients in low-income countries. In high-
income countries, it is standard practice to genotype the virus before starting treatment, to determine 
whether resistance mutations are present. If such genotyping is done and a fully-active combination 
of drugs is chosen, treatment success of patients with transmitted drug resistance is very good. For 
example,  Wittkop  et  al.  (2011)  estimated  that  among  European  patients  with  transmitted  drug 
resistance who were treated with a fully active combination of drugs, 95% had fully suppressed 
viral load after one year. Of the patients who were treated with an insufficiently strong regimen, 
85% had fully suppressed viral load after one year. 
In  low-income  countries,  viral  genotyping  is  usually  not  available.  Therefore,  patients  with 
transmitted  drug  resistance  may  start  insufficiently  strong  ART  regimens,  which  will  be  less 
effective in reducing the viral load, which, in turn, can lead to the evolution of multi-class drug 
resistance. In addition, even if testing is done, fewer second-line treatment options are available for 
patients in low-income countries. 
2. Acquired Drug Resistance during ART 
Since 1996, standard treatment of HIV has been with a combination of three drugs. In principle,  
many combinations can be created from the long list of antiretroviral drugs that are on the market.  
In practice,  only a few combinations  are used for most patients and recommended as first-line 
treatment  for  treatment-naive  patients.  The  most  common  combination  therapy  consists  of  an 
NNRTI and two NRTIs, which is available as a one-pill-a-day treatment. Also common in high-
income countries is the combination of a protease inhibitor (PI) with two NRTIs. This combination 
is only used as second-line therapy (when standard drugs fail) in low-income countries and not 
available as a one-pill-a-day regimen. In order to make PI-based treatment as effective as NNRTI-
based treatment, the blood levels of the PI need to be increased by adding a small dose of another 
protease inhibitor  (ritonavir), which is called boosting. Nowadays, boosted PI regimens are more 
common  than  unboosted  PI  regimens.  Recently,  a  third  option  has  been  added  to  the  list  of 
recommended combinations for treatment-naive individuals: two NRTIs combined with an integrase  
strand transfer inhibitor (INSTI). This combination is also available as a one-pill-a-day regimen. 
The evolution  of  drug resistance on these  combination treatments  is  much less  likely than  the 
evolution of drug resistance on treatments consisting of just one or two drugs, as were common in 
the late 1980s and the first half of the 1990s. Still, drug resistance can evolve during treatment.   
The clearest pattern of acquired drug resistance in patients on ART is that the percentage of patients 
with drug resistance goes up steadily with time on treatment. For example, in a meta-analysis of 
studies from resource-limited settings, Stadeli and Richman (2012) find that 7% of patients who 
have been on ART for 6-11 months have resistance, 11 % after 12 -23 months and 21% after 36  
months  or  more.  A similar  effect  has  been reported  for  patients  in  high-income countries.  For 
example, a large study from the UK (Philips, 2010) reports that the percentage of patients with at 
least one drug-resistance mutation increases from 11 to 14 to 18% after four, six and eight years 
respectively for patients on NNRTI-based treatment. This study shows that even a patient whose 
viral population did not evolve resistance during six years of treatment has a probability of around 
2% to acquire resistance during the next year of treatment. 
In general, treatments based on NNRTIs or unboosted PIs are more susceptible to resistance than 
treatment  based  on  a  ritonavir-boosted  PI  (bPI)  (Kempf  et  al.,  2004).  bPI  regimens  are  less 
susceptible to resistance, partly because resistance to the bPI  itself  is unlikely to evolve, but also 
because, in the presence of the bPI, it  is unlikely resistance evolves to the other drugs that the  
patient is taking (NRTIs). This protective effect of the bPI can be explained, in part, by the low viral 
loads achieved on bPIs. However, Kempf et al. (2004) showed that NRTI resistance is unlikely to 
evolve even in patients with viremia (unsuppressed virus) if they are taking a bPI. The mechanism 
behind this observation is not yet understood. 
NNRTI-based ART is more common in low-income countries than in high-income countries, which 
means that there is a relatively high risk of drug resistance in low-income countries. In addition, if a  
patient's virus acquires drug resistance on NNRTI-based ART, it is less problematic in high-income 
countries  because  it  will  be  discovered  faster  due  to  regular  viral  load  monitoring  and  viral 
genotyping, so that the patient can be switched to second-line treatment when necessary.  
There is a strong association between acquired drug resistance  and  sub-optimal adherence to the 
treatment regimen. For example, Lima et al. (2008) show that drug resistance is more than twice as 
common in patients with 80-95% adherence when compared to patients with adherence levels of 
95%  or  higher.  It  is  clearly  documented  that  structured  treatment  interruptions  lead  to  drug 
resistance (e.g., Danel et al., 2009), likely because an interruption allows for growth of the viral  
population  and leads  to  a  higher  abundance  of  resistance  mutations.  When treatment  is  started 
again, these resistance mutations can quickly rise in frequency and lead to failure (Pennings, 2012). 
It seems plausible that non-adherence leads to drug resistance in exactly same way. In addition, sub-
optimal  adherence can lead to periods of effective monotherapy (the presence of just  one drug 
above the minimally effective concentration) when drugs have very different half-lives. Effective 
monotherapy is  most  likely  to  occur  in  patients  on NNRTI-based treatments,  because  NNRTIs 
typically  have  longer  half-lives  than  NRTIs  (Bangsberg  2006).  However,  the  importance  of 
effective monotherapy for resistance is debated (Pennings 2012).
In low-income countries, there is concern about resistance due to unplanned treatment interruptions 
when patients are faced with stock-outs at the hospital or pharmacy. For example, Marcellin et al.  
(2008) show that treatment interruptions occur in Cameroon due to drug shortages in hospitals.  
3. Multi-class drug resistance
Multi-class  drug resistance typically  occurs  when a virus  that is  resistant  to  one  drug acquires 
resistance to another drug. In principle, it is possible that a virus acquires multiple drug-resistance 
mutations at the same time, but data suggest that this is less common. For example, Harrigan et al  
(2005) analyze data from a large Canadian cohort and show that at any one time, there are more 
patients with drug resistance to one class of drugs than patients with resistance to more than one  
drug. On the other hand, data reviewed by Stadeli and Richman (2012) suggest that in resource-
limited settings, multi-class drug resistance is more common and around three-quarters of patients 
with at least some resistance have multi-class drug resistance. This difference may be due to lack of 
monitoring in  resource-limited settings (Gupta et al., 2009). Unfortunately, data on multi-class drug 
resistance and the effect of monitoring are scarce, but the general belief is that switching quickly 
after detection of the first drug-resistance mutation can prevent the accumulation of further drug-
resistance mutations. If treatment is continued even though one of the drugs no longer works, the 
virus will likely evolve resistance to the other drugs. 
The Plato II study (Nakagawa et al. 2012) showed that, in Europe, the prevalence of patients who 
had failed on all three major drug classes (NRTI, NNRTI and PI) increased steadily after 1996, but 
remained stable from 2005. This is probably because the incidence of multi-class resistance went 
down, which,  in  turn,  can be attributed to  improvements  in  monitoring,  simpler  and less toxic 
regimens, which led to better adherence, and better pharmacodynamics, which made regimes more 
robust to sub-optimal adherence (Lundgren, 2012). As the risk of multi-class drug resistance went 
down, the chances of successful treatment for patients with multi-class resistant virus improved 
over the last decade (Castagliola et al., 2012). This is mainly due to the fact that several new drugs 
entered the market, such as raltegravir (INSTI) and darunavir (PI). When a patient's virus has many 
resistance mutations and an uncommon combination of three or more drugs needs to be used, this is 
referred to as salvage therapy.  
4. Resistance to the newer drugs 
For a  long time  there were  only  three main drug classes  available  for  HIV treatment:  NRTIs, 
NNRTIs  and  PIs,  and  the  drugs  within  these  classes  were  characterized  by  extensive  cross-
resistance.  If  a  patient  had failed treatment  on one NNRTI, it  was unlikely that treatment  with 
another would work. From 2003 multiple new drugs from old and new drug classes entered the 
market. The new drug classes are integrase strand transfer inhibitors (INSTI, such as elvitegravir 
and raltegravir), CCR5 antagonists (maraviroc) and fusion inhibitors (enfuvirtide). 
There are large differences between the genetics of resistance to different drugs, and the new classes 
are no exception. For example, single  mutations can confer resistance to the integrase inhibitors 
raltegravir and elvitegravir, whereas multiple mutations are needed to confer resistance to newer 
integrase inhibitors  (DTG and MK-2048, Mesplède et al., 2012). A single mutation at position 143, 
148  or  155  of  the  integrase  gene  can  make  the  virus  highly  resistant  against  raltegravir.  The 
resistance  profile  of  elvitegravir  is  similar,  and  mutations  at  position  148  and  155  were  also 
observed  in  patients  who  failed  treatment  with  the  “quad”  pill,  a  one-pill-a-day  regimen  that 
contains combistat-boosted elvitegravir and two NRTIs (DeJesus et al., 2012). 
The fusion inhibitor enfuvirtide has been available since 2003, but is not used as first-line therapy, 
partly because it has to be injected subcutaneously by the patient. Several mutations are known to 
confer  resistance  to  enfuvirtide  (Hirsch  et  al.,  2008).  Resistance  against  the  CCR5  antagonist 
maraviroc comes in two distinct flavors. Either, the virus can accumulate mutations that allow it to 
use inhibitor-bound CCR5, or the virus can switch tropism and use CXCR4 instead of CCR5 as a 
co-receptor to enter the cell  (Moore and Kuritzkes,  2009).  The latter  is more common because 
CXCR4-using variants can be present at relatively high frequencies even prior to treatment with a 
CCR5 inhibitor. A recent study based on deep-sequencing found CXCR4-using variants in more 
than 90% of patients, though at very low frequencies in many of them (Swenson et al., 2011).
5. Prevention of mother-to-child transmission (PMTCT)
Pregnant women in low-resource settings are often treated to prevent the transmission of HIV from 
the mother to her child.  The simplest  option,  which is  no longer recommended, is  to use only 
nevirapine (NVP, an NNRTI). A single dose of nevirapine (sdNVP) reduces the probability that the 
child is infected perinatally, but leads to a high risk of drug resistance in the mother and in the child, 
if it  becomes infected despite nevirapine.  In a meta-analysis, Arrivé et  al (2007), found that on 
average 36% of the women treated with sdNVP had detectable NVP resistance several weeks after 
the treatment and 53% of the children. Other studies have shown that women who are previously 
treated with sdNVP are more likely to fail therapy if they are later treated with NNRTI-based ART 
(Lockman et al 2010). For these women, it is better to start with bPI-based ART. 
In Pennings (2012), I show that the high probability of resistance after sdNVP is likely due to the 
combination  of  monotherapy  with  a  high  abundance  of  pre-existing  NNRTI  mutations.  The 
situation is somewhat better if women are treated with the NRTI  zidovudine (ZDV) for at least a 
couple of weeks before receiving sdNVP (Arrivé et al., 2007). Treatment with ZDV reduces the 
viral  load  and  therefore  the  abundance  of  NNRTI  resistance  mutations.  Prior  ZDV treatment 
therefore leads to a lower probability that NNRTI mutations increase in frequency due to sdNVP, 
(Pennings, 2012). The probability of resistance is also reduced if NVP monotherapy is avoided by 
adding a so-called “NRTI tail”, i.e., a combination of two NRTIs (ZDV and 3TC) for one week after  
delivery (Arrivé et al 2007, Pennings, 2012). Alternatively, pregnant women may be treated with a 
three-drug combination therapy throughout their pregnancy and while they are breastfeeding, even 
if they are not eligible for treatment for their own health. 
6. Minority variants 
Standard genotyping assays can only detect variants that have a relatively high frequency in the 
patient (around 20% frequency or higher). In recent years, however, studies have started to use 
methods that can detect low-frequency variants (down to 0.1% frequency, depending on the assay) 
and the presence of such low-frequency resistance mutations is associated with an increased risk of 
virologic failure, i.e., the inability to achieve or maintain suppression of viral replication, due to 
resistance  (Li  et  al.,  2011).  From an evolutionary  perspective,  this  is  entirely  expected.  If  the 
mutation  that  confers  resistance  is  already  present  in  the  patient  before  treatment  starts,  such 
mutation may increase in frequency rapidly after the start of treatment and lead to virologic failure. 
Nonetheless, studies on minority variants have also shown that treatment can be – and often is – 
successful in patients despite the presence of minority variants. This means that even if a mutation 
is present at high enough frequency to be detected, there is no guarantee that it will lead to virologic  
failure. One reason for this may be that even though the mutation leads to resistance to one drug, the 
other  two  drugs  in  the  treatment  can  suppress  the  virus  sufficiently.  Another,  yet  untested, 
possibility is that the location of origin of the detected mutation (e.g., blood vs. spleen) determines 
whether a minority variant increases or decreases in frequency when treatment is  started. More 
research is needed to understand under which circumstances minority variants lead to treatment 
failure. At the same time, it has become clear that treatment can fail in patients even if no minority 
variants are detectable, because new mutations can happen or emerge from the reservoir of latent 
cells (Li et al., 2011). 
There  is  the  hope that  cut-off  values  for  the  frequency of  known resistance  mutations  can  be 
determined to guide treatment decisions (Gianella and Richman 2010). Such a cut-off value would 
mean that a mutation with higher abundance than this value indicates an increased risk of treatment 
failure, whereas the same mutation at an abundance below the cut-off doesn't. From an evolutionary 
perspective, it is improbable that a sharp cut-off value exists, since each resistant viral particle has 
an equal chance to cause treatment failure. The probability of treatment failure is therefore likely to 
grow  roughly  linearly  with  the  abundance  of  a  rare  resistant  variant.  Of  course,  for  clinical 
purposes, a cut-off value may still be determined depending on the probability of failure due to a 
resistance mutation at a given frequency and the benefits gained from prevented failures. 
It may be possible to reduce the risk of failure due to minority variants, without knowing which 
patients carry them, by modifying the way treatment is started. For example, treatment could be 
started with a set of drugs that are not susceptible to drug-resistance (e.g., a bPI-based combination) 
and once the viral load is sufficiently reduced – and therefore the abundance of any minority variant 
is equally reduced – the patient can be switched to the treatment of choice, such as NNRTI-based 
treatment,  which  is  cheaper  and  available  as  a  co-formulated  one-pill-a-day  regimen.  Such  a 
modified start of treatment may be acceptable for all patients, and minority variant assays are not 
needed. 
Assays  for  minority  variants  can  be  useful  to  choose  a  regimen  for  pre-treated  patients.  For 
example, the presence of low-abundance NNRTI mutations in women who were previously treated 
for PMTCT, predicted treatment failure when they started NNRTI-based ART (Boltz et al. 2011). 
Fisher et al. (2012) used a deep sequencing approach and detected minority variants in patients 
failing  bPI-based ART.  Swenson et  al.  (2011) used  a  deep sequencing approach to  predict  the 
success of treatment with a CCR5 inhibitor. 
7. Drug resistance and PrEP
Pre-exposure prophylaxis (PrEP) is the use of antiretrovirals to prevent HIV infection. Trials have 
looked at the effectiveness of tenofovir (TDF) as a pill or a vaginal gel and Truvada (co-formulated 
tenofovir and emtricitabine, TDF/FTC) to prevent infections, with success in some, but not all trials.  
PrEP could, in principle, lead to increased levels of drug resistance in several ways. First of all, the 
prophylactic antiretrovirals  may not work against TDF- or FTC-resistant HIV strains and could 
therefore allow infections with resistant strains,  leading to a higher relative level of transmitted 
drug-resistance (Supervie et al.  2010). Secondly, if someone becomes infected but is still  using 
PrEP,  the antiretrovirals  used for  PrEP could select  for  resistance.  However,  in  the early PrEP 
studies (Grant et al. 2010, Baeten et al. 2012, Abdool Karim et al. 2010), none of the infections that 
occurred  during  the  trial  were  with  drug-resistant  strains,  possibly  because  infections  mainly 
occurred in participants who were not taking their drugs regularly. 
Another  risk  occurs  when patients  start  using  PrEP while  already infected  with  HIV.  This  has 
occurred several times in the early PrEP studies. In the iPrEx study (Grant et al. 2010) two patients 
on the TDF/FTC arm were already infected with HIV, but did not know about it. The result was that 
they were taking TDF/FTC while already infected, which led to resistance in at least one of the two 
patients,  probably  because  the  drugs  are  not  strong enough to  suppress  established  virus  even 
though they can prevent infection. In the Partners PrEP study (Baeten et al. 2012) there were also 
two cases of resistance due to the use of PrEP by previously infected people. These results show 
that unrecognized infections can be a problem for those who take antiretrovirals for PrEP. 
Conclusions 
HIV is known as a fast evolving virus. It earned this reputation in the 1980s when treatments were 
typically only effective for a few months, because drug resistance evolved so quickly. However, 
over the last decades HIV treatments have become better and better at slowing down the evolution 
of drug resistance. Although no patient is entirely protected from drug resistance, rates of acquired 
drug resistance are low, on the order of a few percent per year of treatment. 
Clinical trials, combined with viral load monitoring and viral genotyping, have made it possible to 
find  treatments  that  minimize  the  risk  of  acquired  drug  resistance.  Even  without  a  thorough 
understanding of the mechanisms of the evolution of drug resistance, it is straightforward to count 
the number of  patients with viral  failure  and resistant  virus  in  the various treatment-arms of a 
clinical trial, allowing for a steady improvement of treatment regimens from one trial to the next.  
On the other hand, finding the best way to prevent transmitted drug resistance is a much harder 
problem, mainly because the level of transmitted drug resistance is determined by many factors in a 
community, not just the individual patient. These factors are hard to capture in a trial, plus, such a  
trial would need to compare communities as opposed to patients, which is more costly. Fortunately, 
preventing  acquired  drug  resistance  has  helped  to  keep  levels  of  transmitted  drug  resistance 
relatively low.  
We should not forget that the issue of HIV drug resistance is not yet solved. In fact, drug resistance 
is mostly a problem for patients who also have other problems. For example, a pregnant and HIV-
positive woman who has no access to proper treatment, may get treated with sdNVP to prevent 
mother-to-child transmission. The use of sdNVP can lead to NNRTI resistance, which means that if 
regular treatment becomes available for her later, it may not even work. In addition, if she lives in 
an area where viral load monitoring is not available, she may stay on the failing treatment and 
acquire  additional  drug-resistance mutations,  which,  in  turn,  can compromise the  usefulness  of 
second-line treatments. To solve the problem of drug resistance, the availability of both drugs and 
monitoring needs to increase drastically. 
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List of abbreviations
ART: antiretroviral therapy, usually referring to three-drug regimen of two NRTIs and an NNRTI or 
a PI. 
NRTI: nucleoside/nucleotide analogue reverse transcriptase inhibitor 
NNRTI:  non-nucleoside analogue reverse transcriptase inhibitor
PI: protease inhibitor
bPI: ritonavir-boosted protease inhibitor
INSTI: integrase strand transfer inhibitor 
PMTCT: prevention of mother-to-child transmission
MDR: multi-class drug resistance
PrEP: pre-exposure prophylaxis
TDF: tenofovir (NRTI
FTC: emtricitabine (NRTI)
ZDV: zidovudine (NRTI)
3TC: lamivudine (NRTI)
NVP: nevirapine (NNRTI)
sdNVP: single-dose nevirapine
References
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. a, Grobler, A. C., Baxter, C., Mansoor, L. E.,  
Kharsany, A. B. M., et al. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral 
microbicide,  for  the  prevention  of  HIV  infection  in  women.  Science  (New  York,  N.Y.), 
329(5996), 1168–74. doi:10.1126/science.1193748
Arrivé, E., Newell, M.-L., Ekouevi, D. K., Chaix, M.-L., Thiebaut, R., Masquelier, B., Leroy, V., et 
al.  (2007). Prevalence of resistance to nevirapine in mothers and children after single-dose 
exposure to prevent vertical transmission of HIV-1: a meta-analysis.  International journal of  
epidemiology, 36(5), 1009–21. doi:10.1093/ije/dym104
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., et  
al. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The 
New England journal of medicine, 367(5), 399–410. doi:10.1056/NEJMoa1108524
Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., Parkin, N., et 
al.  (2006).  Adherence-resistance  relationships  for  protease  and  non-nucleoside  reverse 
transcriptase inhibitors explained by virological fitness. AIDS (London, England), 20(2), 223–
31. doi:10.1097/01.aids.0000199825.34241.49
Boltz, V. F., Zheng, Y., Lockman, S., Hong, F., Halvas, E. K., McIntyre, J., Currier, J. S., et al. 
(2011).  Role  of  low-frequency HIV-1 variants  in  failure  of  nevirapine-containing  antiviral 
therapy in women previously exposed to single-dose nevirapine. Proceedings of the National  
Academy  of  Sciences  of  the  United  States  of  America,  108(22),  9202–7. 
doi:10.1073/pnas.1105688108
Castagliola, D., Ledergerber, B., Torti, C., van Sighem, A., Podzamczer, D., Mocroft, A., Dorrucci,  
M.,  et  al.  (2012).  Trends  in  virological  and  clinical  outcomes  in  individuals  with  HIV-1 
infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. 
The Lancet infectious diseases, 12(2), 119–27. doi:10.1016/S1473-3099(11)70248-1
Danel, C., Moh, R., Chaix, M.-L., Gabillard, D., Gnokoro, J., Diby, C.-J., Toni, T., et al. (2009). 
Two-months-off,  four-months-on  antiretroviral  regimen  increases  the  risk  of  resistance, 
compared with  continuous therapy:  a  randomized trial  involving West  African adults.  The 
Journal of infectious diseases, 199(1), 66–76. doi:10.1086/595298
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., et al. 
(2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate 
versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil 
fumarate for initial treatment of HIV-1 infection: a randomised, double-.  Lancet, 379(9835), 
2429–38. doi:10.1016/S0140-6736(12)60918-0
Frentz, D., Boucher, C. A., & van de Vijver, D. A. (2012). Temporal changes in the epidemiology of 
transmission of drug-resistant HIV-1 across the world. AIDS reviews, 14(1), 17–27. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/22297501
Gianella, S., & Richman, D. D. (2010). Minority variants of drug-resistant HIV.  The Journal of  
infectious diseases, 202(5), 657–66. doi:10.1086/655397
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., et al. 
(2010). Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. 
New England Journal of Medicine, 363(27), 2587–2599.
Gupta, R. K., Jordan, M. R., Sultan, B. J., Hill, A., Davis, D. H. J., Gregson, J., Sawyer, A. W., et al. 
(2012). Global trends in antiretroviral resistance in treatment-naive individuals with HIV after 
rollout of antiretroviral treatment in resource-limited settings : a global collaborative study and 
meta-regression analysis in resource limited settings 2001 - 2011. Lancet, 380, 1250–1258.
Harrigan, P. R., Hogg, R. S., Dong, W. W. Y., Yip, B., Wynhoven, B., Woodward, J., Brumme, C. J., 
et al. (2005). Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort 
initiating  triple  antiretroviral  therapy.  The  Journal  of  infectious  diseases,  191(3),  339–47. 
doi:10.1086/427192
Hirsch,  M. S.,  Günthard,  H.  F.,  Schapiro,  J.  M.,  Brun-Vézinet,  F.,  Clotet,  B.,  Hammer,  S.  M.,  
Johnson, V. a, et  al. (2008). Antiretroviral  drug resistance testing in adult HIV-1 infection: 
2008  recommendations  of  an  International  AIDS  Society-USA panel.  Clinical  infectious  
diseases : an official publication of the Infectious Diseases Society of America, 47(2), 266–85. 
doi:10.1086/589297
Johnson, V. a, Calvez, V., Günthard, H. F., Paredes, R., Pillay, D., Shafer, R., Wensing, A. M., et al. 
(2011). 2011 update of the drug resistance mutations in HIV-1.  Topics in antiviral medicine, 
19(4), 156–64. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22156218
Kempf, D. J., King, M. S., Bernstein, B., Cernohous, P., Bauer, E., Moseley, J., Gu, K., et al. (2004). 
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine 
and lamivudine to nelfinavir plus stavudine and lamivudine. The Journal of infectious diseases, 
189(1), 51–60. doi:10.1086/380509
Li, J. Z., Kozal, M. J., Balduin, M., Jakobsen, M. R., Masquelier, B., Johnson, J. A., Miller, M. D.,  
et al. (2011). Low-Frequency HIV-1 Drug Resistance.
Lima, V. D., Gill, V. S., Yip, B., Hogg, R. S., Montaner, J. S. G., & Harrigan, P. R. (2008). Increased 
resilience to the development of drug resistance with modern boosted protease inhibitor-based 
highly  active  antiretroviral  therapy.  The  Journal  of  infectious  diseases,  198(1),  51–8. 
doi:10.1086/588675
Lundgren, J. D., & Lazarus, J. V. (2012). Dampening the effect of drug resistance in HIV: a leap 
forward. The Lancet infectious diseases, 12(2), 91–2. doi:10.1016/S1473-3099(11)70278-X
Marcellin, F., Boyer, S., Protopopescu, C., Dia, A., Ongolo-Zogo, P., Koulla-Shiro, S., Abega, S.-C., 
et al. (2008). Determinants of unplanned antiretroviral treatment interruptions among people 
living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).  Tropical medicine & 
international health : TM & IH, 13(12), 1470–8. doi:10.1111/j.1365-3156.2008.02170.x
Mohapi, L., Stringer, E., Mngqibisa, R., Siika, A., Atwine, D., Hakim, J., Shaffer, D., et al. (2010).  
new england journal, 1499–1509.
Moore, J., & Kuritzkes, D. (2009). A piece de resistance: how HIV-1 escapes small molecule CCR5 
inhibitors. Current Opinion in HIV and AIDS, 4(2), 118–124.  
doi:10.1097/COH.0b013e3283223d46.A
Nakagawa, F., Lodwick, R., Costagliola, D., van Sighem, A., Torti, C., Podzamczer, D., Mocroft, 
A., et al. (2012). Calendar time trends in the incidence and prevalence of triple-class virologic 
failure in  antiretroviral  drug-experienced people with HIV in Europe.  Journal  of  acquired  
immune deficiency syndromes, 59(3), 294–9. doi:10.1097/QAI.0b013e31823fe66b
Pennings, P. S. (2012). Standing genetic variation and the evolution of drug resistance in HIV. PLoS 
computational biology, 8(6), e1002527. doi:10.1371/journal.pcbi.1002527
Phillips, A. N., Dunn, D., Sabin, C., Pozniak, A., Matthias, R., Geretti,  A. M., Clarke, J., et al. 
(2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral  
therapy in routine clinical practice.  AIDS (London, England), 19(5), 487–94. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/15764854
Read, A. F.,  & Huijben, S. (2009). PERSPECTIVE: Evolutionary biology and the avoidance of 
antimicrobial  resistance.  Evolutionary  Applications,  2(1),  40–51.  doi:10.1111/j.1752-
4571.2008.00066.x
Stadeli, K. M., & Richman, D. D. (2012). Rates of emergence of HIV drug resistance in resource-
limited settings: a systematic review. Antiviral therapy. doi:10.3851/IMP2437
Supervie,  V.,  García-Lerma,  J.  G.,  Heneine,  W.,  &  Blower,  S.  (2010).  HIV,  transmitted  drug 
resistance, and the paradox of preexposure prophylaxis. Proceedings of the National Academy  
of Sciences of the United States of America, 107(27), 12381–6. doi:10.1073/pnas.1006061107
UNAIDS. (2007). Towards universal access.
UNAIDS. (2012). Together we will end AIDS (p. UNAIDS / JC2296E).
Wittkop, L., Günthard, H. F., de Wolf, F., Dunn, D., Cozzi-Lepri, A., de Luca, A., Kücherer, C., et 
al. (2011). Effect of transmitted drug resistance on virological and immunological response to 
initial  combination  antiretroviral  therapy  for  HIV  (EuroCoord-CHAIN  joint  project):  a 
European  multicohort  study.  The  Lancet  infectious  diseases,  11(5),  363–71. 
doi:10.1016/S1473-3099(11)70032-9
World Health Organization. (2012). HIV drug resistance report 2012.
